Zydus Life shares jump after pharma firm launches overactive bladder treatment drug in US

Zydus Lifesciences (ZYDUSLIFE) share price news: Zydus Lifesciences (ZYDUSLIFE) shares were in high demand on Monday after the Ahmedabad-headquartered pharmaceutical company launched a generic drug, used in the treatment of overactive bladder, in the US market. The stock of Zydus Lifesciences gained by Rs 31.8, or 3.5 per cent, to end at Rs 954 apiece on BSE after the news. 

Zydus Lifesciences rolled out Mirabegron extended-release tablets in the strength of 25 mg in the US, having received final approval for the drug from the US Food and Drug Administration (USFDA), according to a regulatory filing prior to the market hours on Monday.

With this development, Zydus joins the first suppliers of the generic version of the Mirabegron ER tablets in the US market. 

The drug will be manufactured at the Zydus group's formulation manufacturing facility in Ahmedabad SEZ, India, according to Zydus Lifesciences.

The launch of generic Mirabegron will improve access and availability of the generic product for patients in the US, said Zydus CEO-Americas Punit Patel. 

"This is a significant launch for us which will strengthen our growth plans in the US market in the current fiscal," Patel added.

The 25 mg and 50 mg strengths of the Mirabegron ER tablets have estimated annual sales of $2.4 billion in the US, according to IQVIA MAT data. 

Zydus also plans to launch the tablets in the 50 mg strength in the market.

What are Mirabegron ER tablets used for?

Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.